Glimepirida Pensa

Glimepirida Pensa is a prescription oral medication containing the active ingredient glimepiride, a second‑generation sulfonylurea used for blood‑glucose control in adults with type 2 diabetes mellitus. The product is marketed in the European Union and is supplied in tablet form, although specific strength and dosage form details are not disclosed in the available data.

Glimepirida Pensa is indicated for the management of hyperglycaemia in patients with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

- Improves fasting and post‑prandial blood glucose levels. - Can be combined with metformin or other oral antidiabetic agents when monotherapy is insufficient. - May be used in patients who have not achieved glycaemic targets with lifestyle modification alone. - Suitable for adult patients with preserved pancreatic beta‑cell function. - Often prescribed when a sulfonylurea class drug is appropriate for the individual's clinical profile.

Glimepirida Pensa may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require prompt medical attention.

Common: - Hypoglycaemia (low blood sugar) - Nausea or abdominal discomfort - Headache - Dizziness or light‑headedness - Weight gain

Serious: - Severe hypoglycaemia with loss of consciousness - Allergic reactions such as rash, itching, or swelling - Hepatic dysfunction indicated by elevated liver enzymes - Hematologic abnormalities like leukopenia or thrombocytopenia

Before initiating Glimepirida Pensa, clinicians should evaluate patient history and monitor for potential risks.

- Assess renal and hepatic function; dose adjustments may be needed in impairment. - Use cautiously in elderly patients due to increased hypoglycaemia risk. - Avoid in patients with a history of sulfonylurea hypersensitivity. - Monitor blood glucose regularly to detect and manage hypoglycaemia. - Counsel patients on recognizing symptoms of low blood sugar and appropriate corrective actions. - Review concomitant use of alcohol, which can potentiate hypoglycaemic episodes.

Glimepirida Pensa can interact with several drug classes, influencing its efficacy or safety profile.

Avoid: - Other sulfonylureas or insulin secretagogues, which may cause additive hypoglycaemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glimepiride plasma levels. - Disulfiram, which may potentiate hypoglycaemic effects.

Use with caution: - Beta‑blockers, which can mask hypoglycaemia symptoms. - Thiazide diuretics, potentially enhancing hyperglycaemic effects. - Corticosteroids, which may reduce glucose‑lowering efficacy. - Antidepressants such as SSRIs, which have been reported to affect glycaemic control.